TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07080905: Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B

Sponsor: CSL Behring · Phase: PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 20 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$4,387,800

Rescue Site Savings

+$2,925,200

Unlock Full NCT07080905 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07080905 Rescue Dossier →